Publications
Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy Biesen, Frese-Schaper, Enghard, Cheng, Hiepe and Frese Scand J Rheumatol 2021 Nov 2 - https://pubmed.ncbi.nlm.nih.gov/34726116/
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan Andreas Keil, Sean R. Hall, Meike Körner, Martin Herrmann, Ralph A. Schmid and Steffen Frese Arthritis Research & Therapy, 2016 Oct 22. 18(1): 243 DOI: 10.1186/s13075-016-1144-5 – http://www.ncbi.nlm.nih.gov/pubmed/27770825
The topoisomerase I inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis Andreas Keil, Manuela Frese-Schaper, Selina K. Steiner, Meike Körner, Ralph A. Schmid and Steffen Frese Arthritis & Rheumatology, 2015 Mar 16. doi: 10.1002/art.39119 – http://www.ncbi.nlm.nih.gov/pubmed/25779651
Low-Dose Irinotecan Improves Advanced Lupus Nephritis in Mice Potentially by Changing DNA Relaxation and Anti–Double–Stranded DNA Binding Manuela Frese-Schaper, Andreas Keil, Selina K. Steiner, Mathias Gugger, Meike Körner, Gregor J. Kocher, Lena Schiffer, Hans-Joachim Anders, Uyen Huynh-Do, Ralph A. Schmid and Steffen Frese Arthritis & Rheumatology, Vol. 66, No. 8, August 2014, pp 2259–2269, DOI 10.1002/art.38665 – www.ncbi.nlm.nih.gov/pubmed/24729466, Supplement
Structural modification of DNA – a therapeutic option in SLE? Steffen Frese and Betty Diamond. Nature Reviews Rheumatology, Oct 18;7(12):733-8. doi: 10.1038/nrrheum.2011.153 - www.nature.com/nrrheum/journal/v7/n12/full/nrrheum.2011.153.html
Reversal of Established Lupus Nephritis and Prolonged Survival of New Zealand Black 3 New Zealand White Mice Treated with the Topoisomerase I Inhibitor Irinotecan Manuela Frese-Schaper, Jakob Zbaeren, Mathias Gugger,† Marc Monestier,‡ and Steffen Frese The Journal of Immunology, February 15, 2010 Vol. 184 No. 4 2175-2182, DOI: 10.4049/jimmunol.0903153 – www.jimmunol.org/cgi/doi/10.4049/jimmunol.0903153
Publications
Refractory mixed proliferative and membranous lupus nephritis treated with the topoisomerase I inhibitor irinotecan as add-on therapy Biesen, Frese-Schaper, Enghard, Cheng, Hiepe and Frese Scand J Rheumatol 2021 Nov 2 - https://pubmed.ncbi.nlm.nih.gov/34726116/
The topoisomerase I inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis Andreas Keil, Manuela Frese-Schaper, Selina K. Steiner, Meike Körner, Ralph A. Schmid and Steffen Frese Arthritis & Rheumatology, 2015 Mar 16. doi: 10.1002/art.39119 – http://www.ncbi.nlm.nih.gov/pubmed/25779651
Low-Dose Irinotecan Improves Advanced Lupus Nephritis in Mice Potentially by Changing DNA Relaxation and Anti–Double–Stranded DNA Binding Manuela Frese-Schaper, Andreas Keil, Selina K. Steiner, Mathias Gugger, Meike Körner, Gregor J. Kocher, Lena Schiffer, Hans-Joachim Anders, Uyen Huynh-Do, Ralph A. Schmid and Steffen Frese Arthritis & Rheumatology, Vol. 66, No. 8, August 2014, pp 2259–2269, DOI 10.1002/art.38665 – www.ncbi.nlm.nih.gov/pubmed/24729466, Supplement
Structural modification of DNA – a therapeutic option in SLE? Steffen Frese and Betty Diamond. Nature Reviews Rheumatology, Oct 18;7(12):733-8. doi: 10.1038/nrrheum.2011.153 - www.nature.com/nrrheum/journal/v7/n12/full/nrrheum.2011.153.html
Reversal of Established Lupus Nephritis and Prolonged Survival of New Zealand Black 3 New Zealand White Mice Treated with the Topoisomerase I Inhibitor Irinotecan Manuela Frese-Schaper, Jakob Zbaeren, Mathias Gugger,† Marc Monestier,‡ and Steffen Frese The Journal of Immunology, February 15, 2010 Vol. 184 No. 4 2175-2182, DOI: 10.4049/jimmunol.0903153 – www.jimmunol.org/cgi/doi/10.4049/jimmunol.0903153